A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

Chandra, J., Woo, W. P., Finlayson, N., Liu, H. Y., McGrath, M., Ladwa, R., Brauer, M., Xu, Y., Hanson, S., Panizza, B., Frazer, I. H. and Porceddu, S. V.  A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002)…

Read More

Liaskou, E., Patel, S. R., Webb, G., Bagkou Dimakou, D., Akiror, S., Krishna, M., Mells, G., Jones, D. E., Bowman, S. J., Barone, F., Fisher, B. A. and Hirschfield, G. M.  Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells.  Journal Of Autoimmunity (2018).  doi:10.1016/j.jaut.2018.07.020

Read More